We previously reported that the positive rates of serum CYFRA 21-1, which reacts specifically with cytokeratin-19 fragments, in patients with stage IV or recurrent breast cancer were as high as those for CA 15-3 and superior to those for CEA. The gene discussed is CEACAM5; the disease is breast cancer.